Emerging role of GLP-1 receptor agonists in the treatment of obesity

Lisa M Neff1, Robert F Kushner21Division of Endocrinology, Metabolism, and Molecular Medicine, 2Division of General Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USAAbstract: The prevalence of obesity has increased dramatically in recent decades,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Lisa M Neff, Robert F Kushner
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://doaj.org/article/ab3d151b2fa0441e8cc19b08cb63c808
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:ab3d151b2fa0441e8cc19b08cb63c808
record_format dspace
spelling oai:doaj.org-article:ab3d151b2fa0441e8cc19b08cb63c8082021-12-02T01:36:38ZEmerging role of GLP-1 receptor agonists in the treatment of obesity1178-7007https://doaj.org/article/ab3d151b2fa0441e8cc19b08cb63c8082010-07-01T00:00:00Zhttp://www.dovepress.com/emerging-role-of-glp-1-receptor-agonists-in-the-treatment-of-obesity-a4877https://doaj.org/toc/1178-7007Lisa M Neff1, Robert F Kushner21Division of Endocrinology, Metabolism, and Molecular Medicine, 2Division of General Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USAAbstract: The prevalence of obesity has increased dramatically in recent decades, both in the US and worldwide. Pharmacotherapy can augment the weight-reducing effects of lifestyle modification and can facilitate long-term weight maintenance. However, there is a paucity of pharmacologic agents approved for the treatment of obesity, and the use of existing weight loss medications is frequently limited by contraindications, drug interactions, adverse effects, limited coverage by third-party payers, and cost. In recent years, there has been an increased understanding and appreciation of the role of gastrointestinal hormones in the control of body weight. One such hormone, GLP-1, also plays an important role in glucose homeostasis. GLP-1 receptor agonists, such as exenatide and liraglutide, have been developed and are already approved for the treatment of type 2 diabetes. There has also been interest in the use of GLP-1 receptor agonists for the treatment of obesity in nondiabetic patients. This review explores the potential utility and limitations of exenatide and liraglutide as therapeutic agents for obesity.Keywords: obesity, GLP-1, exenatide, liraglutide Lisa M NeffRobert F KushnerDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2010, Iss default, Pp 263-273 (2010)
institution DOAJ
collection DOAJ
language EN
topic Specialties of internal medicine
RC581-951
spellingShingle Specialties of internal medicine
RC581-951
Lisa M Neff
Robert F Kushner
Emerging role of GLP-1 receptor agonists in the treatment of obesity
description Lisa M Neff1, Robert F Kushner21Division of Endocrinology, Metabolism, and Molecular Medicine, 2Division of General Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USAAbstract: The prevalence of obesity has increased dramatically in recent decades, both in the US and worldwide. Pharmacotherapy can augment the weight-reducing effects of lifestyle modification and can facilitate long-term weight maintenance. However, there is a paucity of pharmacologic agents approved for the treatment of obesity, and the use of existing weight loss medications is frequently limited by contraindications, drug interactions, adverse effects, limited coverage by third-party payers, and cost. In recent years, there has been an increased understanding and appreciation of the role of gastrointestinal hormones in the control of body weight. One such hormone, GLP-1, also plays an important role in glucose homeostasis. GLP-1 receptor agonists, such as exenatide and liraglutide, have been developed and are already approved for the treatment of type 2 diabetes. There has also been interest in the use of GLP-1 receptor agonists for the treatment of obesity in nondiabetic patients. This review explores the potential utility and limitations of exenatide and liraglutide as therapeutic agents for obesity.Keywords: obesity, GLP-1, exenatide, liraglutide
format article
author Lisa M Neff
Robert F Kushner
author_facet Lisa M Neff
Robert F Kushner
author_sort Lisa M Neff
title Emerging role of GLP-1 receptor agonists in the treatment of obesity
title_short Emerging role of GLP-1 receptor agonists in the treatment of obesity
title_full Emerging role of GLP-1 receptor agonists in the treatment of obesity
title_fullStr Emerging role of GLP-1 receptor agonists in the treatment of obesity
title_full_unstemmed Emerging role of GLP-1 receptor agonists in the treatment of obesity
title_sort emerging role of glp-1 receptor agonists in the treatment of obesity
publisher Dove Medical Press
publishDate 2010
url https://doaj.org/article/ab3d151b2fa0441e8cc19b08cb63c808
work_keys_str_mv AT lisamneff emergingroleofglp1receptoragonistsinthetreatmentofobesity
AT robertfkushner emergingroleofglp1receptoragonistsinthetreatmentofobesity
_version_ 1718402978043396096